| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2025―Aug―28 |
Analysis of the course of immune-mediated inflammatory rheumatic diseases after COVID-19: flare frequency and prognostic determinants |
S. T. Abisheva, A. M. Lila, K. S. Rutskaya-Moroshan |
| 2 |
[GO] |
2024―Dez―15 |
Characteristics of the new coronavirus infection (COVID-19) in patients with systemic sclerosis |
M. N. Starovoytova, O. V. Desinova, L. P. Ananieva, O. A. Koneva, L. А. Garzanova, O. B. Ovsyannikova, R. U. Shayakhmetova |
| 3 |
[GO] |
2024―Okt―22 |
Clinical and immunologic abnormalities in COVID-19 |
A. K. Karibova, S. S. Akhmedkhanov, M. T. Kudae, H. M. Malaev |
| 4 |
[GO] |
2024―Aug―22 |
Cutaneous necrotizing vasculitis in a patient with rheumatoid arthritis that developed after COVID-19: description of a clinical case |
R. M. Balabanova, L. N. Denisov |
| 5 |
[GO] |
2024―Jun―16 |
Results of a 24-week open-label, non-interventional study on the efficacy and safety of olokizumab therapy in patients with rheumatoid arthritis after switching from anti-B-cell therapy during the SARS-CoV-2 pandemic |
A. V. Fedorova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, A. A. Akimova, N. A. Ilyina, Yu. D. Kurochkina, Yu. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev |
| 6 |
[GO] |
2023―Aug―21 |
COVID-19 and post-covid syndrome in patients with rheumatoid arthritis |
E. S. Aronova, B. S. Belov, G. I. Gridneva |
| 7 |
[GO] |
2023―Aug―21 |
A clinical case of development of Waterhouse-Friderichsen syndrome after SARS-CoV-2 infection in a patient with rheumatoid arthritis and secondary adrenal AA-amyloidosis |
O. V. Alpidovskaya |
| 8 |
[GO] |
2023―Jul―13 |
Retrospective analysis of cases of multisystem inflammatory syndrome associated with COVID-19 infection in children in the Republic of Komi |
N. N. Korableva, O. R. Payusova, E. V. Berestnev, O. N. Tarbeyeva, A. S. Mezentseva, T. V. Bezuglaya |
| 9 |
[GO] |
2023―Feb―17 |
Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination |
Sh. F. Erdes, B. S. Belov |
| 10 |
[GO] |
2023―Feb―17 |
Clinical case of SARS-CoV-2 infection in a patient with rheumatoid arthritis and secondary AA-amyloidosis of the lungs |
O. V. Vorobeva, L. P. Romanova |
| 11 |
[GO] |
2022―Dez―19 |
Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience |
A. I. Zagrebneva, E. N. Simonova, T. V. Mezenova, N. B. Burmistrova, Yu. A. Gavrikova, Yu. A. Gavrikova, E. O. Morozova, Zh. M. Kodzeva, K. S. Sapogina |
| 12 |
[GO] |
2022―Dez―19 |
Development of bilateral episcleritis and rheumatoid arthritis after a new coronavirus infection: a description of a clinical case |
O. N. Matveeva, E. V. Kvasova |
| 13 |
[GO] |
2022―Okt―20 |
Pathological changes in organs in rheumatoid arthritis with secondary amyloidosis of the heart and kidneys on the background of COVID-19 |
O. V. Vorobeva, I. P. Romanova |
| 14 |
[GO] |
2022―Okt―20 |
Shared features of pathogenetic aspects, autoimmunity and pharmacotherapy in coronavirus infection (COVID-19) and immunoinflammatory rheumatic diseases |
K. S. Rutskaya-Moroshan, S. T. Abisheva, A. M. Lila |
| 15 |
[GO] |
2022―Jun―20 |
Current possibilities of pharmacological correction of neuroimmune joint damage in patients with knee osteoarthritis in long COVID conditions |
I. V. Sarvilina, I. S. Dydykina, A. M. Lila |
| 16 |
[GO] |
2022―Mai―08 |
Analysis of the mechanisms of development of neurorheumatological consequences of COVID-19 and the possibility of their pharmacological correction |
I. V. Sarvilina, A. M. Lila, O. A. Gromova, I. Yu. Torshin, O. A. Shavlovskaya, E. A. Taskina |
| 17 |
[GO] |
2022―Mai―08 |
Use of telemedicine consultations in rheumatology during the COVID-19 pandemic |
O. V. Teplyakova, A. A. Morozova |
| 18 |
[GO] |
2022―Mai―08 |
Organ changes after SARS-CoV-2 infection in a patient with systemic sclerosis according to autopsy |
O. V. Vorobeva, L. P. Romanova |
| 19 |
[GO] |
2022―Feb―20 |
Important aspects of osteoarthritis therapy during the COVID-19 pandemic |
A. M. Lila, A. G. Chuchalin, I. Yu. Torshin, O. A. Gromova |
| 20 |
[GO] |
2022―Feb―20 |
Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data) |
A. N. Kulikov, N. V. Muravyeva, B. S. Belov |
| 21 |
[GO] |
2022―Feb―20 |
COVID-19-associated angiitis: literature review and case report |
D. I. Abdulganieva, N. G. Shamsutdinova, A. A. Gaibaryan |
| 22 |
[GO] |
2021―Okt―20 |
Polyarthritis associated with COVID-19 (clinical case) |
E. S. Aronova, B. S. Belov |
| 23 |
[GO] |
2021―Aug―16 |
Septal panniculitis as manifestation of COVID-19: own data |
O. N. Egorova, R. G. Goloeva, D. I. Abdulganieva |
| 24 |
[GO] |
2021―Apr―24 |
The Prospects of tumor necrosis factor α inhibitors use in patients with COVID-19 |
E. S. Aronova, B. S. Belov |
| 25 |
[GO] |
2020―Mai―31 |
COVID-19: the new challenge for rheumatologists |
B. S. Belov, A. E. Karateev |
